ClinicalTrials.gg
RecruitingNCT07617727Updated Aug 26, 2026

A Phase I Study of JSKN021 in Advanced Solid Tumors

A Phase 1 interventional study of JSKN021 in Advanced Malignant Solid Tumors, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recruiting at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.

02

Conditions studied

  • Advanced Malignant Solid Tumors

Keywords

  • EGFR/HER3
  • JSKN021
03

In context

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form.
  2. Age ≥ 18 years old, male or female.
  3. performance status (ECOG PS) score of 0 or 1.
  4. Expected survival ≥ 3 months.
  5. or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment.
  6. At least one at baseline according to 1.1 criteria.
  7. Adequate organ function.
  8. Female subjects of or male subjects whose partners are of childbearing potential agree to use effective measures.
  9. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
  10. Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.
  11. Adequate of previous therapy before the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Complicated with other malignant tumors within 3 years before the first dose.
  2. History of brainstem, meningeal , spinal cord metastasis or compression, or carcinomatous meningitis; presence of active .
  3. Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula.
  4. Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
  5. Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
  6. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  7. Uncontrolled infection.
  8. Received within 28 days before the first dose, or plan to receive live vaccines during the study period.
  9. Toxicity of previous anti-tumor treatment has not fully or partially recovered.
  10. Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs.
  11. Pregnant and/or lactating women, or planning to become pregnant during the study period.
  12. Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
199 participants (estimated)

Study arms

  • Experimental
    Dose escalation cohort 1

    Drug: JSKN021

  • Experimental
    Dose escalation cohort 2

    Drug: JSKN021

  • Experimental
    Dose escalation cohort 3

    Drug: JSKN021

  • Experimental
    Dose escalation cohort 4

    Drug: JSKN021

  • Experimental
    Dose escalation cohort 5

    Drug: JSKN021

  • Experimental
    Dose escalation cohort 6

    Drug: JSKN021

  • Experimental
    Dose optimization cohort 1

    Drug: JSKN021

  • Experimental
    Dose optimization cohort 2

    Drug: JSKN021

Interventions

  • DrugJSKN021

    JSKN021 administered intravenously at selected dose levels according to protocol

06

What researchers measure

Primary outcomes

  1. Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc (Safety and tolerability of JSKN021)

    Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc.; abnormalities in physical examinations, laboratory tests, electrocardiograms, and other safety measures.

    Time frame: From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.

  2. Dose-limiting toxicity (DLT)

    Incidence of dose-limiting toxicity (DLT) in each dose group.

    Time frame: 21 days from the first dose

  3. Optimal biological dose (OBD) and/or recommended Phase Ⅱ dose (RP2D) of JSKN021.

    Based on safety and efficacy data.

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: Up to 24months

  2. Duration of response (DoR)

    Duration of response (DoR) assessed according to RECIST v1.1.

    Time frame: Up to 24months

  3. Disease control rate (DCR)

    Disease control rate (DCR) assessed according to RECIST v1.1.

    Time frame: Up to 24months

  4. Progression-Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of initial administration till the first documentation of disease progression or death due to any cause (whichever occurs first).

    Time frame: Up to 24months

  5. Overall survival(OS)

    Overall Survival (OS) is defined as the time from the date of initial administration till death due to any cause.

    Time frame: Up to 24months

  6. Immunogenicity

    Incidence and titer changes of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs, if applicable)

    Time frame: Up to 24months

  7. Maximum concentration (Cmax) of JSKN021

    Maximum concentration (Cmax) of JSKN021

    Time frame: Up to 24months

  8. Time to maximum concentration (Tmax) of JSKN021

    Time to maximum concentration (Tmax) of JSKN021

    Time frame: Up to 24 months.

  9. Trough concentration (Ctrough) of JSKN021

    Trough concentration (Ctrough) of JSKN021

    Time frame: Up to 24 months

  10. Area under the concentration-time curve of JSKN021

    Area under the concentration-time curve of JSKN021

    Time frame: Up to 24 months

  11. Volume of distribution (V) of JSKN021

    Volume of distribution (V) of JSKN021

    Time frame: Up to 24 months

  12. Elimination half-life (t1/2) of JSKN021

    Elimination half-life (t1/2) of JSKN021

    Time frame: Up to 24 months

  13. Clearance (CL) of JSKN021

    Clearance (CL) of JSKN021

    Time frame: Up to 24 months

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared. The informed consent form does not include provisions for sharing de-identified participant-level data with researchers outside the study team.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 1, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
May 31, 2029
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617727
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 2, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

Jian Zhang, MD
Contact
syner2000@163.com
08602134778299

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion